1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Jan 2023
Admin
News Article

Novavax Begins Phase 2 Trial For Covid-19-Influenza Combination And Stand-Alone Influenza Vaccine Candidates

Novavax, Inc., A Biotechnology Company Dedicated To Developing And Commercializing Next-Generation Vaccines For Serious Infectious Diseases, Announced The Initiation Of A Phase 2 Trial For Its Covid-19-Influenza Combination (Cic) And Influenza Stand-Alone Vaccine Candidates. The Dose-Confirming Trial Will Evaluate The Safety And Effectiveness (Immunogenicity) Of Different Formulations Of The Cic And Influenza Vaccine Candidates In Adults Aged 50 Through 80."We'Re Encouraged By The Initiation Of This Trial Given The Positive Results Shared Earlier This Year From Our Phase 1/2 Trial, The First Of Its Kind To Evaluate A Combined Covid-19 And Influenza Vaccine," Said Stanley C. Erck, President And Chief Executive Officer, Novavax. "We Believe That Like Influenza, Covid-19 Will Also Be Seasonal Moving Forward, And That There Is Room In The Market For New Alternatives To Provide Better Protection Against The Impact Of Influenza, Particularly In Older Adults, And To Explore The Potential To Combine This With Protection From Covid."The Randomized, Observer-Blinded Trial Will Assess A Combination Of Novavax' Recombinant Protein-Based Covid-19 Vaccine (Nvx-Cov2373), Quadrivalent Influenza Vaccine Candidate, And Patented Saponin-Based Matrix-M Adjuvant. Primary And Secondary Objectives Of The Study Are To Assess The Safety, Tolerability, And Immune Responses To Various Formulations Of The Cic And Influenza Vaccine Candidates. The Phase 2 Dose-Confirmation Trial Will Be Conducted In Two Parts And Seek To Enroll A Total Of Approximately 2,300 Participants Across Multiple Sites Located In Australia And New Zealand.Initial Results Of The Trial Are Expected Mid-Year 2023. These Data Will Inform The Phase 3 Trials For Both Influenza Stand-Alone And Covid-19-Influenza Combination Candidates.Nvx-Cov2373 Is A Protein-Based Vaccine Engineered From The Genetic Sequence Of The First Strain Of Sars-Cov-2, The Virus That Causes Covid-19 Disease. The Vaccine Was Created Using Novavax' Recombinant Nanoparticle Technology To Generate Antigen Derived From The Coronavirus Spike Protein And Is Formulated With Novavax' Patented Saponin-Based Matrix-M

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!